Highlights
• Cash receipts increase to $100,000 in quarter ended 31 March 2019, up from $47,000 in prior quarter
• Cash position of $5.1 million as at 31 March 2019
• O2 Vent® Optima successfully launched in both Australia and Canada during the quarter; US launch expected in mid-CY2019
• Launch of ExVent™ valve technology that integrates with select O2 Vent® devices to naturally improve airflow and airway stability, expected in the quarter ending 30 June 2019
• Strong interest in O2 Vent® devices and Oventus’ Sleep Treatment Platform shown by sleep clinicians and dentists, with agreements expected to be announced during coming quarters
Brisbane, Australia 29 April 2019: Oventus Medical Ltd (ASX: OVN) (Oventus, the Company) announces its Appendix 4C Report for the quarter ended 31 March 2019 and provides a summary of progress
made during the quarter.
For further information please download the attached PDF:
Download this document
